Table 1.
Timeline of disease and treatments.
| Year | Event/Diagnosis | Treatment/Intervention | Response/Outcome |
|---|---|---|---|
| 2018 | Stage IV-B MCL (gastric + marrow involvement) | RV-CAP → R-ESHAP → BEAM-ASCT → Rituximab maintenance | Complete remission |
| 2021 Mar | 1st relapse (extranodal) | HyperCVAD-R/MTX-AraC-R → Ibrutinib | Complete remission |
| 2022 Jun | 2nd relapse (progression on ibrutinib) | Tafasitamab + parsaclisib (clinical trial) | Mixed response → discontinued (hepatitis E) |
| 2023 Nov | Left eye visual loss | Ophthalmologic evaluation → vitrectomy planned | — |
| 2024 Jan-Feb | Vitrectomy confirms intraocular relapse by flow cytometry | Intravitreal methotrexate (bridge) | Partial response (ophthalmological examination) |
| 2024 Mar | CAR-T therapy (Brexucel) | Lymphodepletion + Brexucel infusion | CRS grade 1, no ICANS |
| 2024–2025 | Follow-up | PET-CT complete response; persistent visual impairment in LE | Ongoing remissions |